Researchers uncover how type 2 innate lymphoid (ILC2) and T helper 2 (Th2) cells in allergic asthma survive toxic environments, revealing potential new therapeutic strategies for treatment.
Published: 12/22/2025
The FDA approves depemokimab-ulaa as a long-acting treatment for severe asthma, enhancing patient care with fewer injections and improved outcomes.
Published: 12/17/2025
A study reveals that many asthma patients switch biologics due to perceived ineffectiveness, highlighting the need for personalized treatment strategies.
Published: 12/12/2025
Researchers reveal fibroblasts as key players in hidradenitis suppurativa inflammation, paving the way for innovative treatment strategies.
Published: 12/2/2025
The FDA approves Amneal's albuterol sulfate inhalation aerosol, enhancing access to vital asthma and COPD treatments for millions of Americans.
Published: 12/2/2025
Infants hospitalized with respiratory syncytial virus (RSV) bronchiolitis who were born to parents with asthma had a significantly higher risk of later developing asthma, the investigators found.
Published: 12/1/2025
Thunderstorms significantly increase asthma-related emergency visits, highlighting the need for storm-specific preparedness and management strategies for patients.
Published: 11/26/2025
The findings from the BATURA clinical trial were presented at the 2025 ACAAI Annual Scientific Meeting.
Published: 11/20/2025
Published: 11/19/2025
Depemokimab shows significant improvements in asthma symptoms and peak expiratory flow, supporting its twice-yearly use for severe asthma management.
Published: 11/19/2025
Home monitoring enhances pediatric asthma management, boosting patient engagement and awareness while providing valuable medical feedback for better control.
Published: 11/14/2025
These findings are from the WAYFINDER clinical trial and were presented at the CHEST 2025 Annual Meeting.
Published: 11/3/2025
A new low-carbon albuterol inhaler shows therapeutic equivalence to original options, suggesting reduced emissions and improved sustainability for patients with asthma and other respiratory conditions.
Published: 10/27/2025
The expanded indications now include adolescents with hidradenitis suppurativa aged 12 and older and pediatrics with uveitis aged 2 and older.
Published: 10/17/2025
Higher levels of cyclic adenosine monophosphate (cAMP) may be key to diagnosing asthma and its severity as well as monitoring patients.
Published: 10/13/2025
Cemiplimab's approval is supported by findings from the C-POST clinical trial.
Published: 10/8/2025
Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.
Published: 10/6/2025
Research highlights the effectiveness of the albuterol-budesonide combination for ensuring rapid relief and safety in patients with asthma.
Published: 10/6/2025